Short Stature in Noonan Syndrome: Demography and Response to Growth Hormone Treatment in KIGS Barto J Otten KIGS 10 Year Book, 1999.

Slides:



Advertisements
Similar presentations
Assessing Child Growth in Primary Care Ramesh Mehay, Bradford.
Advertisements

Growth and Nutrition Constantinos J. Stefanidis “P. & A. Kyriakou” Children's Hospital, Athens, Greece.
Approach to the child with short stature
Trends in the Diagnosis and Treatment of Short Stature as Revealed by KIGS Pierre Chatelain KIGS 10 Year Book, 1999.
Turner syndrome(XO) By- Christine & Harpreet!.
Preseted by: Fahd Alareashi & ??????????
Aromatase inhibitors in pediatrics short stature and delayed puberty.
Lung Function Nutrition FEV 1 Percent Predicted vs BMI Percentiles Patients
Growth Hormone Treatment in Some Types of Skeletal Dysplasia and in Some Syndromes with Short Stature in KIGS Olcay Neyzi KIGS 10 Year Book, 1999.
Endocrine Aspects of 11q Is there a role for GH? …no issue Thomas G. Kelly, MD, FAAP Pediatric Endocrinology UC San Diego / Rady Children’s Hospital San.
Growth disturbances Knut Dahl-Jørgensen Unit for Endocrinology and Diabetes Pediatric Dept. Ullevål University Hospital.
Mayfield – Data Handling Lo: To understand which is the appropriate graph to test each hypothesis. To be able to self analyse and adapt my own work.
Turner Syndrome Presentation to TCGI Conference 2008.
Treatment of short stature M. Hashemipour MD Pediatric Endocrinologist Isfahan University of Medical Sciences 1.
BY: Xavier Barnes.  Turner syndrome is a genetic condition that affects development in one in every 2,500 females. Turner Syndrome has a wide-range of.
Primary and Secondary Insensitivity to Growth Hormone in Short Children Otto Mehls University Hospital for Childen and Adolescents Devision of Pediatric.
MD.Trần Thị Bích Huyền Children hospital 1 Endocrine department
TURNER SYNDROME BY STEVEN MOORE. OTHER NAMES Ullrich-Turner syndrome Monosomy X.
Short Stature :Done by Asim .Q. Makhdom. Short Stature :Done by Asim .Q. Makhdom.
Slides presented by the FDA at the Endocrinologic & Metabolic Drugs Advisory Committee meeting on June 10, 2003.
Treatment of Precocious puberty
Common Disorders of Growth and Puberty
Post-natal growth abnormalities ©S Nussey/  IOS.
Normal growth Rafat Mosalli MBBS FRCPC FAAP Rafat Mosalli MBBS FRCPC FAAP 5Th Year Medical students.
Furdela V. PhD assistant prof. Pediatrics department #2
GH Treatment in Children in Remission from Leukaemia and Lymphoma in KIGS Nikolaus Stahnke KIGS 10 Year Book, 1999.
Growth Hormone Treatment in Children with Malignant Cranial Tumours in KIGS Michael B Ranke and David A Price KIGS 10 Year Book, 1999.
Langerhans Cell Histiocytosis: Growth Hormone Treatment over 3 years in KIGS Simon J Howell KIGS 10 Year Book, 1999.
Clinical Methods in Paediatrics DEPARTMENT OF PAEDIATRICS CHINESE UNIVERSITY OF HONG KONG.
{ Box-and-Whisker Plots. Median, Quartiles, Inter-Quartile Range and Box Plots. Measures of Spread The range is not a good measure of spread because one.
Normal growth Dr fatholahpour pediatric endocrinologist
The influence of metabolism, hormones, the properties of bone, dietary life, nutrition, living and social environment make differences in growth and development.
Puberty and Its Pathophysiology
Single middle value The Median The median is the middle value of a set of data once the data has been ordered. Example 1. Robert hit 11 balls at Grimsby.
Development of the KIGS Model for Predicting Growth Response to Growth Hormone Replacement Therapy in Children with Idiopathic Growth Hormone Deficiency.
Continuing the Treatment of Growth Hormone Deficiency During the Transition from Childhood into Adulthood Michael B Ranke and John P Monson KIGS 10 Year.
Growth Hormone Treatment in Children with Intrauterine Growth Retardation and Silver-Russell Syndrome Pierre Chatelain KIGS 10 Year Book, 1999.
Final Height Following Growth Hormone Treatment of Idiopathic Growth Hormone Deficiency in KIGS Wayne S Cutfield, Anders Lindberg, Pierre Chatelain, David.
To graph and interpret Box-and-Whisker Plots 9/17/13 Do Now: Order the set of numbers from least to greatest, then find the median.
Sunrise Teaching 14th April 2016 Susan knox st1 Anne-Marie McClean st3
GnRH agonist various uses in children
GROWTH & GROWTH DISORDERS OLEH Dr. H. Hakimi SpAK Dr. Melda Deliana SpAK Dr. Siska Mayasari Lubis SpA Pediatric Endocrinology USU/ADAM MALIK HOSPITAL.
Growth Hormone Treatment of Children with Prader-Willi Syndrome as Reported to KIGS: First-Year Growth Hormone E Martin Ritzén KIGS 10 Year Book, 1999.
Short stature Dr ali mazaheri MD.
MM2D1: Using sample data, students will make informal inferences about population means and standard deviations b. Understand and calculate the means and.
Short stature Short stature is usually defined as a height below the second (i.e. two standard deviations below the mean) Measuring height velocity is.
Copyright © 2017 American Academy of Pediatrics.
0.24→0.37 mg/kg/week (▲) and 0.37 mg/kg/week ().
Copyright © American Speech-Language-Hearing Association
Precocious or early puberty in patients with
Recapping: Distribution of data.
Figure 1. Serum B-ALP levels in normal male (•) and female (○) children as a function of age. Serum B-ALP levels were increased during infancy and puberty.
Prof. Rai Muhammad Asghar Head of Paediatric Department
Copyright © 2002 American Medical Association. All rights reserved.
兒童生長評估 小兒科 蔡孟哲.
Understanding growth and puberty using the RCPCH UK 2-18 growth charts
Nutritional Assessment –The Right Perspective
A: Box plot comparing the average changes in HbA1c between surgery and medical/lifestyle treatments in the first reports of the 11 RCTs published to date.
Box Plots Example A car park attendant makes a record every hour of the number of cars in the car park work out the.
Differences in the glycated hemoglobin (HbA1c) levels.
Box-And-Whisker Plots
#significant difference versus baseline (P<.05).
Relationship between karyotype and basal characteristics at GH start
Fig.1. The dose of GH administered to patients in different age groups after 1 year of GH replacement therapy. Data are shown as mean, median and 10th-90th.
Height velocity (cm/yr) Height velocity (cm/yr)
Box-And-Whisker Plots
Comparison between groups
Growth rate (cm/yr) Estrogen at age 12 Estrogen at age 15
4, 4, 5, 6, 8, 8, 8, 9, 9, 9, 10, 12 Example 1: Draw a Box plot for the data below Drawing a Box Plot. Lower Quartile.
Sodium consumption (mg/day) at baseline by demographic characteristics in a cohort of self-referred patients with type 2 diabetes. Sodium consumption (mg/day)
Presentation transcript:

Short Stature in Noonan Syndrome: Demography and Response to Growth Hormone Treatment in KIGS Barto J Otten KIGS 10 Year Book, 1999

B J Otten - KIGS 10 Year Book, 1999 Auxological characteristics of all patients with Noonan Syndrome at the start of GH treatment Ta, Tanner et al (1966); Ra, Ranke et al (1988) WHI, weight-for-height index; PAH, projected adult height

B J Otten - KIGS 10 Year Book, 1999 (1/2) Height of male patients (n=101) with Noonan syndrome at the start of GH treatment, prepubertal;, in puberty;, no information on puberty;, median;, + 2 SD;, -4 SD (Noonan- specific standards; Ranke et al 1988) Shaded area, normative standards (Tanner et al 1966) Chronological age (years) Height (cm)

B J Otten - KIGS 10 Year Book, 1999 (2/2) Height of female patients (n=42) with Noonan syndrome at the start of GH treatment, prepubertal;, in puberty;, no information on puberty;, median;, + 2 SD;, -4 SD (Noonan- specific standards; Ranke et al 1988) Shaded area, normative standards (Tanner et al 1966) Chronological age (years) Height (cm)

B J Otten - KIGS 10 Year Book, 1999 Growth response of 57 prepubertal patients with Noonan syndrome to 1 year of GH therapy compared with predicted model for first-year growth response in Turner syndrome Predicted height velocity (cm/years) Studentised residuals

Response to GH therapy of patients with Noonan Syndrome (cross-sectional and longitudinal data for boys and girls) B J Otten - KIGS 10 Year Book, 1999 (1/6)

B J Otten - KIGS 10 Year Book, 1999 Response to GH therapy of patients with Noonan Syndrome (cross-sectional and longitudinal data for boys and girls) (2/6)

B J Otten - KIGS 10 Year Book, 1999 Response to GH therapy of patients with Noonan Syndrome (cross-sectional and longitudinal data for boys and girls) (3/6)

B J Otten - KIGS 10 Year Book, 1999 Response to GH therapy of patients with Noonan Syndrome (cross-sectional and longitudinal data for boys and girls) (4/6)

B J Otten - KIGS 10 Year Book, 1999 Response to GH therapy of patients with Noonan Syndrome (cross-sectional and longitudinal data for boys and girls) (5/6)

B J Otten - KIGS 10 Year Book, 1999 Response to GH therapy of patients with Noonan Syndrome (cross-sectional and longitudinal data for boys and girls) (6/6)

Response to 3 years of GH therapy of 26 patients (boys, n = 20; girls, n = 6) with Noonan Syndrome B J Otten - KIGS 10 Year Book, 1999 Data are shown as box plots, with medians (rules), means (dots), 25th-75th percentiles (shaded boxes) and 10th-90th percentiles (whiskers) p <0.05 (n = 26) Start Years on GH therapy Parental corrected height SDS

B J Otten - KIGS 10 Year Book, 1999 Auxological characteristics of all patients with Noonan Syndrome discontinued from KIGS Ta, Tanner et al (1966); Ra, Ranke et al (1988) (1/2)

B J Otten - KIGS 10 Year Book, 1999 Auxological characteristics of all patients with Noonan Syndrome discontinued from KIGS Ta, Tanner et al (1966); Ra, Ranke et al (1988) (2/2)

B J Otten - KIGS 10 Year Book, 1999 Characteristics of Noonan patients on GH therapy close to final height Ta, Tanner et al (1966); Ra, Ranke et al (1988) (1/2)

B J Otten - KIGS 10 Year Book, 1999 Characteristics of Noonan patients on GH therapy close to final height Ta, Tanner et al (1966); Ra, Ranke et al (1988) (2/2)